Latest news with #Nektar
Yahoo
11-04-2025
- Business
- Yahoo
Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00
Shares of Nektar Therapeutics (NKTR, Financials) rose 26.21% to $0.50 as of 11:36 a.m. ET Friday after Jefferies upgraded the stock from Hold to Buy and increased its price target from $1.00 to $2.00. The firm's revised rating comes ahead of the expected second-quarter topline data from a Phase 2b study of Rezpeg, Nektar's experimental treatment for atopic dermatitis. Warning! GuruFocus has detected 7 Warning Signs with NKTR. The company has lost over 63% of its market value in the past six months, but Jefferies analyst Roger Song cited encouraging results from a Phase 1b trial, which showed a favorable safety and efficacy profile for Rezpeg, an IL-2 Treg stimulator. Song said the drug's novel mechanism of action sets it apart from other current and pipeline treatments in the space. According to Jefferies, the significant negative enterprise value and high liquidityreflected in a current ratio of 4.26support a more favorable risk-reward scenario. Nektar's market capitalization is currently around $93 million. The firm also pointed to Nektar's cash position of $269.1 million at the end of 2024, which is expected to fund operations through the fourth quarter of 2026. The company recently beat consensus earnings expectations, reporting a fourth-quarter 2024 earnings per share of $0.03, compared with an anticipated loss of $0.16. However, revenue for the quarter came in slightly below forecast at $29.2 million versus $29.81 million. Nektar has entered a $75 million equity distribution agreement to support its financial flexibility. The biotech firm is progressing with clinical development for Rezpeg, which is also being studied for alopecia areata and Type 1 diabetes. Other analysts have issued varying outlooks. Oppenheimer raised its rating to Outperform with a $6.00 price target, while BTIG maintained a Neutral stance with a $4.00 target. This article first appeared on GuruFocus.
Associated Press
20-03-2025
- Business
- Associated Press
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
SAN FRANCISCO, March 20, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 27, 2025 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time – webcast link here The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: A replay of the presentation will be available for 30 days. If you would like to request a one-on-one meeting with company management during the conference, please reach out to your respective H.C. Wainwright representative. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit and follow Nektar on LinkedIn. Contact: For Investors: Corey Davis, Ph.D. LifeSci Advisors, LLC [email protected] 212-915-2577 Ahu Demir, Ph.D. LifeSci Advisors, LLC 212-915-3820 For Media: Madelin Hawtin LifeSci Communications 603-714-2638
Yahoo
13-03-2025
- Business
- Yahoo
Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
Cash and Investments: $269.1 million at the end of 2024. Revenue: $29.2 million for Q4 2024; $98.4 million for the full year 2024. R&D Expenses: $28.7 million for Q4 2024; $120.9 million for the full year 2024. G&A Expenses: $17.1 million for Q4 2024; $76.8 million for the full year 2024. Net Income: $7.3 million for Q4 2024; net loss of $119 million for the full year 2024. Earnings Per Share: $0.03 basic and diluted for Q4 2024; $0.58 basic and diluted loss per share for the full year 2024. Gain from Sale: $40.4 million gain from the sale of the Huntsville manufacturing facility. 2025 Revenue Guidance: Expected between $40 million and $50 million. 2025 R&D Expense Guidance: Expected between $110 million and $120 million. 2025 G&A Expense Guidance: Expected between $60 million and $65 million. Cash Runway: Expected to extend into Q4 2026. Warning! GuruFocus has detected 8 Warning Signs with NKTR. Release Date: March 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Nektar Therapeutics (NASDAQ:NKTR) completed enrollment for its Phase IIB studies in atopic dermatitis and alopecia areata on schedule, demonstrating strong interest from patients and physicians. The company has a strong financial position with a cash runway extending into the fourth quarter of 2026, ending 2024 with $269 million in cash and investments. REZPEG, Nektar's lead autoimmune pipeline program, has shown potential as a novel treatment option with a unique immunomodulating mechanism, offering hope for more durable treatment options. Nektar Therapeutics (NASDAQ:NKTR) has expanded its pre-clinical pipeline in immunology and inflammation, advancing its TNFR2 agonist antibody program, NKTR-0165, with plans for an IND submission in the second half of 2025. The company has formed a clinical trial agreement with TrialNet to investigate REZPEG in type 1 diabetes, highlighting its commitment to addressing unmet needs in autoimmune diseases. Nektar Therapeutics (NASDAQ:NKTR) reported a net loss of $119 million for the full year 2024, indicating ongoing financial challenges. The company's revenue for 2024 was $98.4 million, which may not be sufficient to offset its R&D and G&A expenses. There is uncertainty regarding the efficacy of REZPEG in its Phase IIb trials, with the company aiming to replicate promising Phase Ib results. The competitive landscape for atopic dermatitis and alopecia areata treatments is highly competitive, posing challenges for market penetration. The company's reliance on forward-looking statements introduces risks and uncertainties that could impact future performance and outcomes. Q: How are you thinking about dose response across the three dose arms in the atopic dermatitis study? A: Jonathan Zalevsky, Chief Research and Development Officer, explained that they addressed dose response with three different cohorts evaluating both dose level and regimen. Two cohorts evaluated the 24 microgram per kilogram dose, one twice a month and the other once a month, to model the pharmacodynamic profile of Tregs. The third cohort used an 18 microgram per kilogram dose twice a month, chosen to be higher than the 12 microgram per kilogram used in Phase Ib, which showed lower efficacy. Q: What efficacy bar on EASI or IGA would be commercially viable for advancing REZPEG into pivotal development? A: Jonathan Zalevsky noted that they are looking to replicate the Phase Ib results, which showed a dramatic separation from placebo and an 83% change from baseline. They also consider efficacy in the range of Dupixent, the current standard of care, as a successful outcome. The novel mechanism of REZPEG, which has shown a remittive effect, is expected to be appreciated in the underserved market. Q: What is the scope of data planned for the top line Phase II atopic dermatitis results release, and what secondary endpoints should be looked for? A: Jonathan Zalevsky mentioned that the focus will be on the 16-week induction data to provide a directional understanding of the drug's performance. The greatest impact in the first-line setting would be achieved through efficacy, and they aim to replicate the marked results from Phase Ib. The novel mechanism of REZPEG, offering durable responses and low-frequency dosing, is expected to impact the market significantly. Q: Can you provide updates on the timing or expectations for the interim PFS results from the JAVELIN Bladder Medley study? A: Jonathan Zalevsky stated that the results are expected in the middle of the year, as it is an event-driven analysis. The goal is to improve PFS and potentially OS compared to single-agent BAVENCIO in the post-chemo setting. The study is designed to test the combination of NKTR-255 plus BAVENCIO versus BAVENCIO alone. Q: How do you expect the patient baseline in the Phase II atopic dermatitis trial to impact the placebo arm? A: Jonathan Zalevsky hopes for baseline EASI scores in the range of 25 to 30, which have been linked with lower placebo responses and better studies. They implemented several prospective features, such as limiting the US footprint and focusing on experienced dermatologists, to protect the study from high placebo response rates. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
13-03-2025
- Business
- Yahoo
Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
Cash and Investments: $269.1 million at the end of 2024. Revenue: $29.2 million for Q4 2024; $98.4 million for the full year 2024. R&D Expenses: $28.7 million for Q4 2024; $120.9 million for the full year 2024. G&A Expenses: $17.1 million for Q4 2024; $76.8 million for the full year 2024. Net Income: $7.3 million for Q4 2024; net loss of $119 million for the full year 2024. Earnings Per Share: $0.03 basic and diluted for Q4 2024; $0.58 basic and diluted loss per share for the full year 2024. Gain from Sale: $40.4 million gain from the sale of the Huntsville manufacturing facility. 2025 Revenue Guidance: Expected between $40 million and $50 million. 2025 R&D Expense Guidance: Expected between $110 million and $120 million. 2025 G&A Expense Guidance: Expected between $60 million and $65 million. Cash Runway: Expected to extend into Q4 2026. Warning! GuruFocus has detected 8 Warning Signs with NKTR. Release Date: March 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Nektar Therapeutics (NASDAQ:NKTR) completed enrollment for its Phase IIB studies in atopic dermatitis and alopecia areata on schedule, demonstrating strong interest from patients and physicians. The company has a strong financial position with a cash runway extending into the fourth quarter of 2026, ending 2024 with $269 million in cash and investments. REZPEG, Nektar's lead autoimmune pipeline program, has shown potential as a novel treatment option with a unique immunomodulating mechanism, offering hope for more durable treatment options. Nektar Therapeutics (NASDAQ:NKTR) has expanded its pre-clinical pipeline in immunology and inflammation, advancing its TNFR2 agonist antibody program, NKTR-0165, with plans for an IND submission in the second half of 2025. The company has formed a clinical trial agreement with TrialNet to investigate REZPEG in type 1 diabetes, highlighting its commitment to addressing unmet needs in autoimmune diseases. Nektar Therapeutics (NASDAQ:NKTR) reported a net loss of $119 million for the full year 2024, indicating ongoing financial challenges. The company's revenue for 2024 was $98.4 million, which may not be sufficient to offset its R&D and G&A expenses. There is uncertainty regarding the efficacy of REZPEG in its Phase IIb trials, with the company aiming to replicate promising Phase Ib results. The competitive landscape for atopic dermatitis and alopecia areata treatments is highly competitive, posing challenges for market penetration. The company's reliance on forward-looking statements introduces risks and uncertainties that could impact future performance and outcomes. Q: How are you thinking about dose response across the three dose arms in the atopic dermatitis study? A: Jonathan Zalevsky, Chief Research and Development Officer, explained that they addressed dose response with three different cohorts evaluating both dose level and regimen. Two cohorts evaluated the 24 microgram per kilogram dose, one twice a month and the other once a month, to model the pharmacodynamic profile of Tregs. The third cohort used an 18 microgram per kilogram dose twice a month, chosen to be higher than the 12 microgram per kilogram used in Phase Ib, which showed lower efficacy. Q: What efficacy bar on EASI or IGA would be commercially viable for advancing REZPEG into pivotal development? A: Jonathan Zalevsky noted that they are looking to replicate the Phase Ib results, which showed a dramatic separation from placebo and an 83% change from baseline. They also consider efficacy in the range of Dupixent, the current standard of care, as a successful outcome. The novel mechanism of REZPEG, which has shown a remittive effect, is expected to be appreciated in the underserved market. Q: What is the scope of data planned for the top line Phase II atopic dermatitis results release, and what secondary endpoints should be looked for? A: Jonathan Zalevsky mentioned that the focus will be on the 16-week induction data to provide a directional understanding of the drug's performance. The greatest impact in the first-line setting would be achieved through efficacy, and they aim to replicate the marked results from Phase Ib. The novel mechanism of REZPEG, offering durable responses and low-frequency dosing, is expected to impact the market significantly. Q: Can you provide updates on the timing or expectations for the interim PFS results from the JAVELIN Bladder Medley study? A: Jonathan Zalevsky stated that the results are expected in the middle of the year, as it is an event-driven analysis. The goal is to improve PFS and potentially OS compared to single-agent BAVENCIO in the post-chemo setting. The study is designed to test the combination of NKTR-255 plus BAVENCIO versus BAVENCIO alone. Q: How do you expect the patient baseline in the Phase II atopic dermatitis trial to impact the placebo arm? A: Jonathan Zalevsky hopes for baseline EASI scores in the range of 25 to 30, which have been linked with lower placebo responses and better studies. They implemented several prospective features, such as limiting the US footprint and focusing on experienced dermatologists, to protect the study from high placebo response rates. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
13-03-2025
- Business
- Yahoo
Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say
For the quarter ended December 2024, Nektar Therapeutics (NKTR) reported revenue of $29.18 million, up 22.1% over the same period last year. EPS came in at $0.15, compared to -$0.22 in the year-ago quarter. The reported revenue represents a surprise of -25.23% over the Zacks Consensus Estimate of $39.02 million. With the consensus EPS estimate being -$0.13, the EPS surprise was +215.38%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Nektar performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Product sales: $12.87 million versus the eight-analyst average estimate of $9.76 million. The reported number represents a year-over-year change of +134.8%. Revenue- Non-cash royalty revenue related to sale of future royalties: $16.24 million versus $15.15 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a -10.1% change. Revenue- License, collaboration and other revenue: $0.06 million versus the four-analyst average estimate of $28.26 million. The reported number represents a year-over-year change of -81.5%. View all Key Company Metrics for Nektar here>>>Shares of Nektar have returned +23.5% over the past month versus the Zacks S&P 500 composite's -8.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Nektar Therapeutics (NKTR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
